Our previous work demonstrated that combined inhibition of STAT3 and BCR-ABL1 induced synthetic lethality in therapy-resistant CML cell lines and patient samples [19, 20]. The gene discussed is STAT3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.